Cargando…
Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
Lung cancer is the most common solid tumor in the worldwide. Targeted therapy and immunotherapy are important treatment options in advanced non-small cell lung cancer (NSCLC). The association of PTEN mutation and tumor immunotherapy is less established for patients with NSCLC. We present the case of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168362/ https://www.ncbi.nlm.nih.gov/pubmed/35677433 http://dx.doi.org/10.3389/fphar.2022.714408 |
_version_ | 1784720991610470400 |
---|---|
author | Teng, Junjie Zhou, Kai Lv, Dongxiao Wu, Changshun Feng, Hong |
author_facet | Teng, Junjie Zhou, Kai Lv, Dongxiao Wu, Changshun Feng, Hong |
author_sort | Teng, Junjie |
collection | PubMed |
description | Lung cancer is the most common solid tumor in the worldwide. Targeted therapy and immunotherapy are important treatment options in advanced non-small cell lung cancer (NSCLC). The association of PTEN mutation and tumor immunotherapy is less established for patients with NSCLC. We present the case of an Asian woman diagnosed with stage IV lung adenocarcinoma harboring an ERBB2 mutation. She received Nivolumab treatment when her disease progresses after previous chemotherapy and Afatinib treatment. However, the patient did not response to Nivolumab. PTEN mutation was detected by next-generation sequencing (NGS) after treatment with Nivolumab. PTEN, a secondary mutation, may be served as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma. The relationship between PTEN mutation and immunotherapy is complex and needs further study. |
format | Online Article Text |
id | pubmed-9168362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91683622022-06-07 Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma Teng, Junjie Zhou, Kai Lv, Dongxiao Wu, Changshun Feng, Hong Front Pharmacol Pharmacology Lung cancer is the most common solid tumor in the worldwide. Targeted therapy and immunotherapy are important treatment options in advanced non-small cell lung cancer (NSCLC). The association of PTEN mutation and tumor immunotherapy is less established for patients with NSCLC. We present the case of an Asian woman diagnosed with stage IV lung adenocarcinoma harboring an ERBB2 mutation. She received Nivolumab treatment when her disease progresses after previous chemotherapy and Afatinib treatment. However, the patient did not response to Nivolumab. PTEN mutation was detected by next-generation sequencing (NGS) after treatment with Nivolumab. PTEN, a secondary mutation, may be served as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma. The relationship between PTEN mutation and immunotherapy is complex and needs further study. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9168362/ /pubmed/35677433 http://dx.doi.org/10.3389/fphar.2022.714408 Text en Copyright © 2022 Teng, Zhou, Lv, Wu and Feng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Teng, Junjie Zhou, Kai Lv, Dongxiao Wu, Changshun Feng, Hong Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma |
title | Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma |
title_full | Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma |
title_fullStr | Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma |
title_full_unstemmed | Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma |
title_short | Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma |
title_sort | case report: pten mutation induced by anti-pd-1 therapy in stage iv lung adenocarcinoma |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168362/ https://www.ncbi.nlm.nih.gov/pubmed/35677433 http://dx.doi.org/10.3389/fphar.2022.714408 |
work_keys_str_mv | AT tengjunjie casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma AT zhoukai casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma AT lvdongxiao casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma AT wuchangshun casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma AT fenghong casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma |